{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002901","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.559032+00:00","generated_at":"2026-06-18T12:00:57.915107+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immuneering reports Q4 2022 net loss $13.2M; cash runway into Q4 2024; first patient dosed in IMM-1-104 trial","bullets":["Net loss $13.2M ($0.50/share) for Q4 2022 vs $10.8M ($0.42/share) in Q4 2021; full year net loss $50.5M ($1.91/share).","Cash, cash equivalents and marketable securities $105.5M as of Dec 31, 2022; cash runway extended into Q4 2024 after suspending neuroscience programs.","First patient dosed in Phase 1/2a trial of IMM-1-104 for advanced solid tumors with any RAS mutation; initial PK/safety data expected mid-2023.","IND filing for IMM-6-415 expected Q4 2023; preclinical data presented at SITC 2022.","R&D expenses $9.9M in Q4 2022 vs $7.9M in Q4 2021; G&A $4.1M vs $3.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002901","json":"https://secwatch.observer/filing/0001558370-23-002901.json","markdown":"https://secwatch.observer/filing/0001558370-23-002901.md","text":"https://secwatch.observer/filing/0001558370-23-002901.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000155837023002901/0001558370-23-002901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000155837023002901/imrx-20230306x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:00:57.915107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67e83c4881d72224ecf327a08b99f1de9f1ab929","claim":"Immuneering Corp reported financial results for the quarter and full-year ended December 31, 2022.","evidence_excerpt":"On March 6, 2023, Immuneering Corporation (the “Company”) announced its financial results for the quarter and full-year ended December 31, 2022 and provided business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000155837023002901/0001558370-23-002901-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full-year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}